scholarly journals Transient Efficacy of Tofacitinib in Alopecia Areata Universalis

2016 ◽  
Vol 8 (1) ◽  
pp. 102-106 ◽  
Author(s):  
Florian Anzengruber ◽  
Julia-Tatjana Maul ◽  
Jivko Kamarachev ◽  
Ralph M. Trüeb ◽  
Lars E. French ◽  
...  
Keyword(s):  
Treatment Option ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Autoimmune Disorder ◽  
Immunosuppressive Drugs ◽  
Hair Follicles ◽  
Janus Kinase ◽  
Individual Treatment ◽  
Immune Therapies ◽  
New Treatment

Alopecia areata is a common autoimmune disorder that targets hair follicles. Swarms of lymphocytes surround the basis of the follicles, inducing loss of pigmented terminal hair and subsequently inhibit further hair growth. Depending on the extent of involvement, alopecia areata can be associated with a dramatic reduction of quality of life. Currently, no targeted treatment option is available, and topical immune therapies or immunosuppressive drugs are typically used with mixed success. Recently, several cases of alopecia areata responding to Janus kinase inhibitors were published. Here, we report on a businessman with alopecia areata universalis who was treated with tofacitinib. We observed initial signs of hair regrowth in the same timeframe as previously reported, but efficacy quickly waned again, leading to renewed effluvium. Thus, even though tofacitinib and ruxolitinib are a promising new treatment option, we have yet to learn more about their potential role in each particular patient's individual treatment strategy.

Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

Dermatology ◽  
2018 ◽  
Vol 235 (2) ◽  
pp. 130-136 ◽  
Author(s):  
Nawaf Almutairi ◽  
Tarek M. Nour ◽  
Nasser Haji  Hussain
Keyword(s):  
Hair Loss ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Autoimmune Disorder ◽  
Janus Kinase ◽  
Open Label ◽  
Janus Kinase Inhibitors ◽  
Hair Regrowth ◽  
Significant Difference

Background: Alopecia areata (AA) is a common autoimmune disorder characterized by patchy hair loss. There are many treatments available for AA. However, treatments of severe forms of AA are not satisfactory. Recently, oral Janus kinase (JAK) inhibitors were found to be effective for the treatment of severe AA variants. Objective: The aim of this work was to evaluate and compare the efficacy, side effects, and durability of two oral JAK inhibitor medications (ruxolitinib and tofacitinib) in the treatment of severe AA. Methods: This study included 75 patients with AA with more than 30% scalp hair loss, alopecia totalis, and alopecia universalis randomized into 2 groups. The first group (n = 38) received ruxolitinib 20 mg twice daily, and the second group (n = 37) received oral tofacitinib 5 mg twice daily. The treatment continued for 6 months followed by 3 months of follow-up off therapy. Efficacy of treatment was assessed by monitoring the change in the Severity of Alopecia Tool (SALT) score. Results: Both tofacitinib and ruxolitinib induced remarkable hair regrowth, with a mean change in SALT score of 93.8 ± 3.25 in the ruxolitinib group and 95.2 ± 2.69 in the tofacitinib group. However, the ruxolitinib group showed a shorter duration for initial hair regrowth. There was no statistically significant difference between the groups regarding hair regrowth at the end of the 6-month treatment and relapse rate at the end of the 3-month follow-up. Around two thirds of cases experienced relapse. Both drugs were well tolerated, with no reported serious adverse effects. Conclusion: Both ruxolitinib and tofacitinib could be considered effective and well-tolerated treatments for extensive AA.

The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review

2019 ◽  
Vol 32 (5) ◽  
Author(s):  
Ana B. Oliveira ◽  
Miguel Alpalhão ◽  
Paulo Filipe ◽  
João Maia‐Silva
Keyword(s):  
Systematic Review ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Janus Kinase Inhibitors

JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study

Rheumatology ◽  
2021 ◽  
Author(s):  
Tom Le Voyer ◽  
Cyril Gitiaux ◽  
François-Jérôme Authier ◽  
Christine Bodemer ◽  
Isabelle Melki ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
Retrospective Study ◽  
Skin Disease ◽  
Kinase Inhibitors ◽  
Immunosuppressive Drugs ◽  
Janus Kinase ◽  
High Rate ◽  
Inactive Disease ◽  
Muscle Involvement ◽  
New Onset

Abstract Objective To evaluate the efficacy and safety of Janus kinase inhibitors (JAKis) in JDM. Methods We conducted a single-centre retrospective study of patients with JDM treated by JAKi with a follow-up of at least 6 months. Proportion of clinically inactive disease (CID) within 6 months of JAKi initiation was evaluated using PRINTO criteria and skin Disease Activity Score. Serum IFN-α concentration was measured by Simoa assay. Results Nine refractory and one new-onset patients with JDM treated with ruxolitinib (n = 7) or baricitinib (n = 3) were included. The main indications for treatment were refractory muscle involvement (n = 8) and ulcerative skin disease (n = 2). CID was achieved in 5/10 patients (two/two anti-MDA5, three/four anti-NXP2, zero/three anti-TIF1γ-positive patients) within 6 months of JAKi introduction. All responders could withdraw plasmatic exchange, immunoadsorption and other immunosuppressive drugs. The mean daily steroid dose decreased from 1.1 mg/kg (range 0.35–2 mg/kg/d) to 0.1 (range, 0–0.3, P = 0.008) in patients achieving CID, and was stopped in two. Serum IFN-α concentrations were elevated in all patients at the time of treatment initiation and normalized in both responder and non-responder. A muscle biopsy repeated in one patient 26 months after the initiation of JAKi, showed a complete restoration of muscle endomysial microvascular bed. Herpes zoster and skin abscesses developed in three and two patients, respectively. Conclusion JAKis resulted in a CID in a subset of new-onset or refractory patients with JDM and may dramatically reverse severe muscle vasculopathy. Overall tolerance was good except for a high rate of herpes zoster infection.

scholarly journals APPLICATION OF JANUS-KINASE INHIBITORS IN THE TREATMENT OF ALOPECIA AREATA (LITERATURE REVIEW)

2019 ◽  
Vol 22 (1-2) ◽  
pp. 61-64
Author(s):  
Anfisa A. Lepekhova ◽  
L. M Chernyavskaya
Keyword(s):  
Literature Review ◽  
Mechanism Of Action ◽  
Alopecia Areata ◽  
Kinase Inhibitors ◽  
Janus Kinase ◽  
Targeted Drugs ◽  
Efficacy And Safety ◽  
Janus Kinase Inhibitors ◽  
Immune Mediated ◽  
Adults And Children

Based on the analysis of data from modern foreign sources current information about using of Janus-kinase inhibitors, in particular, tofacitinid and ruxolitinid, for the treatment of alopecia areata in adults and children, in the presence of a lesion of the scalp and other areas (eyebrows, eyelashes) is shown. The information about the mechanism of action of Janus-kinase inhibitors, the efficacy and safety of their use, possible methods of use, prospects for further research in the treatment of alopecia areata using targeted drugs is presented. The pathogenetic rationale for the possibility of using this group of drugs for treating immune-mediated diseases, for instance, alopecia areata is described.

scholarly journals Non-surgical treatment of vitiligo

2020 ◽  
Vol 63 (12) ◽  
pp. 741-747
Author(s):  
Chong Won Choi
Keyword(s):  
Surgical Treatment ◽  
Kinase Inhibitors ◽  
Calcineurin Inhibitors ◽  
Autoimmune Disorder ◽  
Skin Lesions ◽  
Ultraviolet B ◽  
Janus Kinase ◽  
Treatment Modalities ◽  
Pigmented Lesions ◽  
Non Surgical Treatment

Vitiligo is an acquired depigmenting skin disorder that affects 0.5% to 2% of the population. Skin lesions from vitiligo, white macules and patches on the skin, can pose a substantial psychological burdencan, causing a significant decrease in one’s quality of life. Recent basic and clinical studies have found that vitiligo is an autoimmune disorder, mediated by CD8+ T-cell and interferon-γ-mediated cytokine/chemokines. Although no treatment modality presents a complete cure for vitiligo, current treatment modalities have a modest effect on vitiligo by reversing the disease’s progression, inducing its stabilization, and promoting melanocyte regeneration. Current non-surgical treatment modalities include topical corticosteroids, topical calcineurin inhibitors, systemic corticosteroids, and phototherapy such as narrowband ultraviolet B phototherapy and excimer laser. In addition, clinicians have used and combined non-surgical treatment modalities based on the activity and extent of vitiligo. Moreover, considering the high risk of vitiligo relapse, maintenance therapy for re-pigmented lesions has also been introduced. Lastly, based on the results of recent translational research, new and emerging treatment modalities have been introduced, such as Janus kinase inhibitors. This review presents an overview of the current non-surgical treatment modalities for vitiligo and discusses emerging treatments.

Sign in / Sign up

Export Citation Format

Share Document